Since cancer cells often have dysregulated G1 checkpoints, particularly due to P53 mutation or deletion, they are considered to be more dependent on the CHEK1‐mediated intra‐S and G2/M checkpoints, providing an exploitable therapeutic vulnerability.6, 7, 8. This evidence concerns the gene CHEK1 and cancer.